Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis
Santa Mammana(University of Catania), Katia Mangano(University of Catania), Maria Cristina Petralia(University of Messina), James A. McCubrey(East Carolina University), Maria Sofia Basile(University of Catania), Emanuela Mazzon(Centro Neurolesi Bonino Pulejo), Placido Bramanti(Centro Neurolesi Bonino Pulejo), Eugenio Cavalli(Centro Neurolesi Bonino Pulejo), Ferdinando Nicoletti(University of Catania), Paolo Fagone(University of Catania)
Cited by 98
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508
The neuropathic pain: An overview of the current treatment and future therapeutic approaches
|International Journal of Immunopathology and Pharmacology|2019|495